Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways
Open Access
- 12 June 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1399065
Abstract
Lipids, the primary constituents of the cell membrane, play essential roles in nearly all cellular functions, such as cell-cell recognition, signaling transduction, and energy provision. Lipid metabolism is necessary for the maintenance of life since it regulates the balance between the processes of synthesis and breakdown. Increasing evidence suggests that cancer cells exhibit abnormal lipid metabolism, significantly affecting their malignant characteristics, including self-renewal, differentiation, invasion, metastasis, and drug sensitivity and resistance. Prominent oncogenic signaling pathways that modulate metabolic gene expression and elevate metabolic enzyme activity include phosphoinositide 3-kinase (PI3K)/AKT, MAPK, NF-kB, Wnt, Notch, and Hippo pathway. Conversely, when metabolic processes are not regulated, they can lead to malfunctions in cellular signal transduction pathways. This, in turn, enables uncontrolled cancer cell growth by providing the necessary energy, building blocks, and redox potentials. Therefore, targeting lipid metabolism-associated oncogenic signaling pathways could be an effective therapeutic approach to decrease cancer incidence and promote survival. This review sheds light on the interactions between lipid reprogramming and signaling pathways in cancer. Exploring lipid metabolism as a target could provide a promising approach for creating anticancer treatments by identifying metabolic inhibitors. Additionally, we have also provided an overview of the drugs targeting lipid metabolism in cancer in this review.Keywords
This publication has 266 references indexed in Scilit:
- Therapeutic efficacy of FASN inhibition in preclinical models of HCCHepatology, 2022
- Lipid metabolism in cancer progression and therapeutic strategiesMedcomm, 2020
- Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growthThe Prostate, 2019
- Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeuticsWIREs RNA, 2018
- The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma modelInternational Journal of Cancer, 2018
- Dual inhibition of Wnt and Yes‐associated protein signaling retards the growth of triple‐negative breast cancer in both mesenchymal and epithelial statesMolecular Oncology, 2018
- Inhibition of the sterol regulatory element‐binding protein pathway suppresses hepatocellular carcinoma by repressing inflammation in miceHepatology, 2017
- Nonalcoholic Fatty Liver DiseaseJAMA, 2015
- A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed GlioblastomaArchives of Neurology, 2010
- Peroxisome Proliferator-Activated Receptor γ Induces Pancreatic Cancer Cell ApoptosisBiochemical and Biophysical Research Communications, 2001